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Abstract
Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single
disease-specific targets. For Alzheimer’s disease (AD), the focus is the amyloid beta peptide (Aß) that mediates familial
Alzheimer’s disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug
discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than
exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic
molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a
transgenic AD mouse model.
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Introduction
At present, there are few drugs that improve the memory
deficits associated with normal aging and none that prevent
cognitive decline in chronic neurodegenerative conditions such as
Alzheimer’s disease (AD). Except for the rare cases of familial AD,
the cause of AD is not known, but the disease is highly correlated
with aging, a process involving a wide variety of physiological
changes. Therefore, it is likely that the cells in the aging brain are
compromised not from a single cause but from the convergence of
multiple insults. However, the currently most widely used
approach to drug discovery is to identify a single molecular target
and then make a drug that alters this target [1]. Unfortunately,
drugs for AD that were developed through this approach have all
failed in clinical trials, perhaps because one target is not sufficient
or because the targets are also critical for normal brain function so
that their inactivation results in toxicity. Therefore, a different
approach to drug discovery for AD is needed [2], [3].
Since age is the prime risk factor for AD as well as many other
neurodegenerative conditions, we developed a drug screening
procedure that is based upon old age-associated pathologies
without requiring pre-selected molecular targets. A series of cell
culture assays were brought together that mimic multiple pathways
of CNS nerve cell damage and we required that a drug candidate
show efficacy in all of these assays before it could be moved
forward into AD animals. The assays include the loss of trophic
support, oxidative stress, the reduction of energy metabolism (in
vitro ischemia and glucose starvation) and amyloid toxicity. As
potential lead drug candidates to screen in these assays, we chose a
representative from the original pharmacopeia, plant-based
polyphenolics. Natural products have a wide range of molecular
targets because they resemble biosynthetic intermediates to a
greater extent than synthetic drugs and are therefore able to
compete with substrates for multiple enzymes [4].
Curcumin is a curry spice with multiple biological activities that
is also effective in transgenic AD mouse models [5], [6]. To
improve the potency and pharmacokinetic properties of curcumin,
we synthesized a series of hybrid molecules between curcumin and
cyclohexyl-bisphenol A (CBA), a compound that has neurotrophic
activity which curcumin lacks [7]. The best compound in our
initial library was CNB-001, a molecule that has improved stability
over curcumin and that is neuroprotective in multiple neurotox-
icity assays in which curcumin is inactive [8]. We then generated a
large number of derivatives of CNB-001 and selected the best
compound on the basis of activity in our multiple toxicity assays.
The result was a much more potent molecule called J147. It was
then asked if J147 is effective in two paradigms of age-associated
pathology, AD and memory. It is shown here that this broadly
neuroprotective compound has the ability to enhance memory in
normal animals as well as to prevent memory deficits in AD
transgenic mice. The neurotrophic and memory-enhancing
activities of J147 are associated with an increase in brain derived
neurotrophic factor (BDNF) levels and the expression of BDNF
responsive proteins, the enhancement of LTP, synaptic protein
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27865preservation, the reduction of markers for oxidative stress and
inflammation, the reduction of amyloid plaques, and lower levels
of soluble Ab1–42 and Ab1–40. These pleiotrophic effects of a single
molecule suggest that J147 has potential for the treatment of AD.
Results
Because many of the pathological consequences of AD are
enhanced features of the stresses that occur with old age [9], we
devised a drug discovery scheme that uses multiple assays to test
efficacy against these distinct stresses. We started with a multi-
target natural product, curcumin [3], and required that synthetic
derivatives have both improved medicinal chemical properties and
lower EC50s in all of our assays of age-related stresses, not just one.
Figure 1 summarizes this approach. Briefly, a pyrazole derivative
of curcumin called CNB-001 (Figure 1A) is neuroprotective in
multiple cell culture assays designed to reflect the various cellular
toxicities associated with AD [8]. Figure 2 shows the assays that
were used to select the best compounds and presents a comparison
between curcumin and CNB-001. Because aromatic hydroxyl
groups may be covalently modified in vivo by sulfation and
carbohydrate addition thereby limiting brain penetration [10],
derivatives of CNB-001 were synthesized that did not contain
hydroxyl groups but still maintained its biological activities. A
limited structure-activity relationship (SAR) analysis of CNB-001
showed that the hydroxyl groups are not necessary for activity and
that activity was maintained following the addition of two methyl
groups to the nitrogen-associated aromatic ring of CNB-001
(Fig. 1B, CNB-023. Table 1). To improve the pharmacological
properties of CNB-023 and explore the possibility that two
aromatic rings connected by a nitrogen containing bridge are
sufficient for activity, a large number of molecules were
synthesized in a single reaction, followed by the selection of the
most active compound in the mix and the determination of its
structure. To generate diversity, we carried out a reaction between
2,4 dimethylphenyl hydrazine and m-anisaldehyde under condi-
tions which generate a wide variety of reaction products. The
reaction products were then separated initially by thin layer
chromatography (TLC) followed by reverse phase chromatogra-
phy. Biological activity was followed by three primary rat cortical
neuron culture assays that are detailed below; an assay for trophic
factor activity [11]; [8], a glutamate-induced oxidative stress assay
called oxytosis [12], and amyloid toxicity toward hippocampal
neurons [13]. When the most active TLC fraction was separated
on a HPLC column, only one peak was effective in all three assays
(Fig. 1D). The structure of this compound was determined by
NMR spectroscopy and confirmed by synthesis and crystal
structure (Figs. 1C and D). It was designated J147 (Fig. 1C).
J147 has the medicinal chemical properties of a good CNS drug
candidate with respect to size (351 MW), cLogP (4.5), total polar
surface area (41.9) and pharmacokinetics (not shown) [14]. Also
included in the legend of Fig. 1 is an abbreviated list of assays used
to identify both potential drug targets and screens to identify
potential toxicities. To date there is no evidence for potential side
effects, nor has a molecular target been identified. As detailed
below, J147 also has a low EC50 in multiple neurotoxicity assays.
J147 is Broadly Neuroprotective
Since the original lead compound, CNB-001, was selected on
the basis of its broad neuroprotective activity [8] and J147 on the
basis of a subset of these activities, it was first asked if J147
maintained all of the activities of CNB-001. Figure 2 shows that
J147 is biologically active in six assays that represent distinct
neurotoxicity pathways related to aging and neurodegenerative
disease. In one assay of trophic factor withdrawal (TFW), primary
embryonic cortical cells are plated at low density in serum-free
medium (Fig. 2A). At low density, the cells die within two days but
can be rescued by combinations of neurotrophic growth factors,
but not by one alone [[11] and unpublished]. In contrast, cell
death is prevented by J147 alone with an EC50 of 25 nM. In a
second assay, J147 is able to rescue a clone of the hippocampal
nerve cell line HT22 expressing the BDNF receptor, transmem-
brane receptor kinase B (TrkB), from serum starvation under
conditions where the cells can be protected by BDNF (Fig. 2B)
[15]. J147 is equally neuroprotective using cells lacking TrkB,
showing that J147 does not require the BDNF receptor for activity.
Figure 2C shows that J147 also rescues primary cortical neurons
from oxytosis, an oxidative stress-induced programmed cell death
pathway caused by glutathione (GSH) depletion [12]. A reduction
in GSH is a common denominator of old age and essentially all
chronic CNS diseases [16]. J147 is also neuroprotective against
glucose starvation (Fig. 2D) and the loss of energy metabolism in
an in vitro ischemia model (Fig. 2E) [17], [18]. Finally, J147 is able
to block extracellular amyloid toxicity using rat hippocampal
neurons with an EC50 of about 200 nM (Fig. 2F). J147 does not,
however, bind to and directly inhibit Ab1–42 aggregation using the
thioflavin S assay (not shown), as do its precursors curcumin and
CNB-001 [8], [6]. Curcumin is only marginally active in two
neuroprotection assays [8], the trophic factor withdrawal and Ab
toxicity assays, at the indicated concentrations (Fig. 2 A and F),
while CNB-001 is significantly less effective than J147 in all assays.
These data show that our drug discovery scheme is effective at
identifying a highly potent neuroprotective molecule. J147 has
neurotrophic and BDNF-like activities that are independent of the
BDNF receptor, TrkB (Fig. 2B). BDNF is a molecule that is also
involved in promoting memory, is reduced in the brain with age,
and in AD as well as in other neurological disorders [19], [20],
[21], and it has long been considered a drug target for AD [22].
J147 Enhances Long-Term Potentiation and Memory
Given the association between memory, BDNF and AD, we first
asked whether or not J147 could affect long-term potentiation
(LTP) in hippocampal slices. LTP is considered a good model of
how memory is formed at the cellular level. Although J147 had no
direct effect on basal synaptic transmission in the CA1 area of rat
hippocampal slices (Fig. 3A), it induced LTP in slices exposed to a
weak titanic stimulation (15 pulses at 100 Hz), which by itself
failed to induce LTP (Fig. 3B). The LTP facilitating effect of J147
was concentration-dependent in the range of 0.01–1 mM (Fig. 3C).
An inactive analog of J147 (2187–88) in which the two nitrogens
were replaced by carbons had no activity in this assay (Fig. 3D).
It has recently become possible to identify early presymptomatic
stages of AD in which there is minimal cognitive impairment, the
best time to initiate treatment [23]. Current measures of outcome
in AD clinical trials require a significant improvement in cognition
for FDA approval, but none of the recently developed drugs
showed such an effect in clinical trials and may require very long
treatment durations to achieve significance. Therefore, we asked if
J147 is active in promoting learning and memory following a
short-term treatment using multiple assays in normal animals.
These assays include the novel object recognition (NOR) test in
rats, and the novel object location (NOL) test, Barnes and Y mazes
in mice; they all measure various aspects of spatial learning and
memory. The innate exploratory nature of rodents can be used to
assess memory using the NOR and NOL tests [24], for both
require habituation where the rodent becomes familiar with
objects in certain locations. The habituation period is followed by
the testing period where the animal is exposed to a novel object in
A Cognitive Enhancing Drug For Alzheimer’s Disease
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NOR test, during the habituation period rats were presented with
two identical objects, which they explored for a fixed time period.
Memory is assessed one day later when two objects are presented,
one of which was presented previously during the training and is
thus familiar; while the other object is new to them. It is
hypothesized that memory for the familiar object results in more
time exploring the novel object. J147 was administered orally to
the rats before the start of the habituation period to assess its
effects on memory, specifically consolidation of the familiar object.
Figure 4A shows that oral administration of J147 only one hour
prior to the habituation period enhanced memory of the familiar
object in the rat NOR test. There was a statistically significant
increase in the recognition index following all 3 doses of J147. A
Figure 1. Selection of J147. CNB-001 (A) is a broadly neuroprotective and neurotrophic derivative of curcumin [8]. CNB-023 (B) is a derivative of
CNB-001 lacking hydroxyl groups but with similar activity that was identified by SAR analysis of CNB-001. The boxed area shows the hypothesized
biologically active fragment of CNB-023. A large collection of molecules around this chemical space was generated by the reaction of m-anisaldehyde
with 2.4 dimethylphenyl hydrazine (see Materials and Methods) and J147 (C) was selected from the reaction products on the basis of its activity in
trophic factor withdrawal (TFW), oxidative stress (oxytosis) and Ab toxicity assays (see Figure 2). (D) Final HPLC run of reaction mixture that generated
J147. The structure of the most active product (fraction 10) was determined by NMR. J147 was then synthesized, and its crystal structure (insert)
determined, confirming its biological activity and structural identity. The following are de-risking and target identification screens, with no significant
reproducible hits. J147 was used at 10 micromolar unless indicated. (1) LeadProfiling+P450 screen. Over 60 CNS receptors and transporters (work
done by MDS Pharma). (2) hERG (work done by MDS and Absorption Systems). (3) Acute toxicity in rats. Negative at 2 grams/kilogram (work done by
Absorption systems). (4) CeeTox ‘‘Safe’’ up to 90 micromolar plasma concentration (work done by CEETOX, INC). (5) 352 protein kinases (done by
Ambit). (6) MDRI-MDCK brain penetration classification ‘‘High’’ (work done by Absorption Systems). (7) Enzyme Assays. Cox 1; Cox 2; Lox 5,12,15; Sirt
1,2,3; LT4 hydrolase; LTC4 synthase; cathepsin B; matrix metalloprotease 1; phosphodiesterases 10A1, 11A1, 1A, 2A, 3A, 4A1A, 4B1, 5A, 6, 7A, 7B, 8A1,
9A2; proteasome (done by MDS). (8) Enzyme assays. PPARa, c; deubiquitinases, BAP1, UCH-L1, L3, USP5; acetylcholine esterase; MAOA; MAOB;
phosphatases (19 of them), proteases and caspases (8) (done by Caliper).
doi:10.1371/journal.pone.0027865.g001
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(Fig. 3D), was also inactive in the NOR test (not shown). The
positive control for this assay was the acetylcholinesterase
inhibitor, galantamine, injected IP at 3 mg/kg. J147 is not,
however, an acetylcholinesterase inhibitor or a phosphodiesterase
inhibitor (PDI) as assayed against acetylcholinesterase and 12 PDIs
at 10 mM, (MDS Pharma Services, not shown). The inhibition of
both enzymes promotes memory and both are drug targets for
memory enhancement [25], [26]. Therefore, the mode of action of
J147 on memory may be distinct from the traditional memory
enhancing drugs.
To explore the ability of chronic J147 treatment to stimulate
various aspects of memory in young mice, they were fed J147 at
200 ppm (10–20 mg/kg/day) in their chow. After 2 wks on J147
chow, they were sequentially assayed in the Barnes maze, Y-maze
and NOL. The NOL test relates to spatial short-term recognition
memory where the exploration of a novel object over repeated
trials and its subsequent change in location assays the ability of
mice to build up spatial representations of their environment. J147
treated mice demonstrated a greater difference between the final
trial with the old location and the trial with the new location
(P=0.0006 vs. P=0.017) yielding a significant difference in the
recognition index (F(1,22)=2.5, P,0.05; Fig. 4B). This result
demonstrates that J147 treatment resulted in an improvement in
spatial memory in these mice.
To assay the ability of J147 to alter another aspect of memory,
we used the Y maze. The spontaneous tendency to alternate free
choices in entering the 3 arms of the Y maze is a measure of short-
term memory [27], [28]. The groups did not differ in overall
numbers of arm entries, suggesting that activity levels were not
altered by J147 treatment. However, J147 treated mice made a
higher percentage of spontaneous alternations (defined as
Figure 2. Biological Activities of J147. J147 is active with EC50 s between 10 and 200 nM in six different assays for neurotrophic activity and
neurotoxicity. o-o, J147; x-x, CNB-001; D-D, curcumin. (A) Trophic Factor Withdrawal. Primary cortical neurons were prepared from 18-day-old rat
embryos and cultured at low cell density with or without the three compounds. Cell viability was assayed 2 days later. (B) BDNF-like Activity. HT22
cells expressing the TrkB (BDNF) (open circles, J147) receptor or no TrkB (black circles, J147) were placed in serum-free medium in the presence of
50 ng/ml BDNF or the indicated amounts of compounds. Cell viability was determined 2 days later. Curcumin had no activity in this assay up to one
micromolar. BDNF was used at 50 ng/ml and active only in cells expressing TrkB (open bar), not in its absence (black bar). (C) Oxidative Stress. E18 rat
cortical neurons were treated with 5 mM glutamate and different concentrations of compounds one day after plating when no ionotropic glutamate
receptors are expressed. Cell viability was measured 24 hr later. (D) Glucose Starvation. PC12 cells were starved for glucose plus or minus 20 nM J147,
0.2 mM CNB-001 or 10 mM curcumin and cell viability determined 48 hr later. J147 and NGF increase cell viability in the absence of glucose, *P,0.001
vs. control. CNB-001 and curcumin are inactive at 0.2 and 10 mM respectively (curcumin not shown). (E) Chemical ischemia. HT22 cells were treated
with 20 mM iodoacetic acid for 2 hr alone or in the presence of varying concentrations of J147, CNB-001 or curcumin. Percent survival was measured
after 24 hr. (F) Amyloid toxicity. Primary hippocampal cells were exposed to 5 mMA b1–42 in the presence of increasing amounts of compounds and
cell viability determined 48 hr later. All data shown are mean 6 SEM, n=3 or 4. The curcumin and CNB-001 data which were included for comparison
with J147 have been presented, in part, previously [8], [84].
doi:10.1371/journal.pone.0027865.g002
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F(1,22)=3.3, P=0.0032) (Fig. 4C). These data indicate that
J147 improves short-term memory.
The Barnes maze assay is also a spatial learning and memory
test [29]. It is less stressful and physically taxing than the Morris
w a t e rm a z ea n ds u i t a b l ef o rs t u d i es in all ages and abilities of
mice. In addition, the strategies used by the animals to perform
the task are readily revealed. Mice were trained to find an
escape tunnel among 20 choices in a circular platform for 3
blocks of 3 days each for the acquisition phase. The retention
test for long-term memory was done 6 weeks later with the
escape tunnel in the same position. The escape tunnel was then
moved to a new location and the behavior of the mouse
recorded (the reversal test). Although there was no statistically
significant differences between groups (F(1,22)=2.9, P.0.05),
there were trends toward decreased errors in the J147 group in
block 1 (F(1,22)=2.0, P=0.057) and block 3 (F(1,22)=1.8,
P=0.086) trials in the acquisition phase (Fig. 4D). Importantly,
a greater proportion of J147-treated mice used a spatial strategy
to locate the escape chamber in block 3 (z=2.33, P=0.019)
(Fig. 4E and H). This difference appeared to hold during the
retention (memory) test (Fig. 4F, I), where the J147 treated mice
made significantly fewer errors than control mice (F(1,22)=2.6,
P=0.01) (Fig. 4D). There was no group difference in errors
made when the escape chamber was moved in the reversal test
(Fig. 4D). However, a greater number of J147 mice utilized a
sequential strategy during this test (Fig. 4G, J), suggesting that
they adopted a working memory strategy in the face of change.
J147-treated mice used more optimal strategies in the Barnes
maze, resulting in superior spatial memory as evidenced in the
retention test. Therefore, J147 meets the initial criterion of a
drug for AD in that it has the ability to enhance several different
aspects of memory with short-term treatment in multiple animal
models.
Table 1. Structure activity relationship of a few CNB-001
derivatives.
Compound R1 R2 R3 Ab -E C 50 HT22 - EC50
CNB-001 OH OMe H 460 nM 1.8 mM
CNB-020 H H H .10 mM .10 mM
CNB-022 H OMe H 2 mM5 mM
CNB-026 OMe OMe H .10 mM .10 mM
SK37H H OMe 4-Et 500 nM 1 mM
CNB-077 H OMe 4-Me 400 nM 1 mM
H OMe 2,4-di-Me 400 nM 560 nM
The structure of CNB-001 is shown in Figure 1A. A series of CNB-001 derivatives
were synthesized with the goal of removing the hydroxyl group and
maintaining and/or improving biological activity in the glutamate based
oxytosis assay and extracellular amyloid toxicity. Et (ethyl), Me (Methyl).
doi:10.1371/journal.pone.0027865.t001
Figure 3. J147 Facilitates the Induction of LTP in Schaffer Collateral CA1 Pyramidal Cell Synapses in Rat Hippocampal Slices. (A)
Effect of J147 (1 mM) on basal synaptic transmission. Hippocampal slices were exposed to J147 during the time indicated by the black bar. The fEPSP
slope is expressed as the percentage of the value immediately before the addition of J147. J147 does not affect basal synaptic transmission. (B) J147
facilitates the induction of LTP after a weak tetanic stimulation (15 pulses at 100 Hz) which alone does not induce LTP in control slices. The effect of
J147 is concentration-dependent. Time course of changes in the fEPSP slope. The hippocampal slices were untreated (o, n=9) or exposed to J147 (.,
0.01 mM, n=6; m, 0.1 mM, n=5;N
,1mM, n=7) for the time indicated by the black bar and weak tetanic stimulation was applied at time 0. The fEPSP
slope is expressed as the percentage of the value immediately before the application of weak tetanic stimulation. (C) Concentration-dependency. To
compare the data among the groups, the averages of the fEPSP slopes 30–60 min after tetanic stimulation were calculated as an index of LTP
magnitude. J147 demonstrated a concentration dependent effect with 1000 nM having the greatest effect on the fEPSP slope (n=7 slices per rat:
one-way ANOVA F(3,23)=4.4, **P=0.01). (D) Negative Control. 2187–88, the alkene form of J147 in which nitrogens are replaced by carbons (o, n=9;
m, 0.1 mM, n=5;N
,1mM, n=5) showed no effect. All data shown are means 6 SEM.
doi:10.1371/journal.pone.0027865.g003
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Animal Model
Since J147 is orally active in memory assays in normal animals,
we asked if it could prevent the behavioral deficits in a transgenic
mouse model of AD. The line 85 APPswe/PS1/DE9 transgenic
AD mouse (huAPP/PS1) was used because there is an extensive
literature on their pathology and behavior [30], [31], [32], [33].
There is good pathology (plaques and loss of synaptic markers) at 9
months along with clear deficits in the Morris water maze (MWM)
assay. The transgenic mice were fed J147 in their chow at
200 ppm starting at 4 mo of age. This dose was chosen based
upon the potency of J147 in the memory assays (Fig. 4). Since we
Figure 4. Behavioral Assays. (A) The novel object recognition test (NOR) was employed for compound J147. Doses of 1, 2 and 5 mg/kg were
administered by oral gavage to 7 wk old Sprague-Dawley rats 1 hr prior to training. Treatment with J147 increased the recognition index with all
three concentrations. Galantamine, injected IP at 3 mg/kg, served as a positive control, one-way ANOVA F (3, 40)=12.9. *P,0.05 n=12 per group
(Done by Behavioral Pharma, La Jolla, CA). In panels B-J normal male C57BL/6J mice were fed J147 at 200 ppm for 2 wks and the Barnes maze assay
was then done, which required 8 weeks to complete. This was followed by the novel object location (NOL) and Y-maze assays. (B) Novel object
location (NOL) assay; the assay was performed similarly to (A) except that one object was used and it was moved to a new location instead of being
replaced by another. J147 treated mice had significantly greater recognition indexes than control mice in this assay (n=12 per group: one-way
ANOVA F(1,22)=2.5, *P,0.05). (C) Y-maze. The tendency of rodents to sequentially explore 3 arms of the Y-maze is a measure of short-term memory.
While the groups did not differ in total arm entries, mice fed J147 exhibited a higher percentage sequential entries into all 3 arms (spontaneous
alterations). F(1,22)=3.3 p=0.0032. (D) The error rate in the acquisition phase of the Barnes maze, 9 consecutive days, pooled data from 3 days per
block. A lower error rate indicates better learning. The difference between control (white bar) and J147-fed mice (black bar) in Blocks 1 and 3 are
almost significant (n=12 per group: one-way ANOVA F(1,22)=2 and F(1,22)=1.8, respectively, P.0.05 for both). Six weeks after the final acquisition
phase, mice were re-assayed and J147 significantly improved memory (retention test) (n=12 per group: one-way ANOVA F(1,22)=2.6, *P,0.01) but
had no effect when the escape tunnel was relocated (reversal test). (E–J) The strategy used by the mice to find the escape tunnel was determined
from videotapes and mice fed J147 tended to use a spatial strategy rather than sequential or random ones (z=2.33, P=0.019 for Block 3; z=1.73,
P=0.80 for retention). All data shown are means 6 SEM.
doi:10.1371/journal.pone.0027865.g004
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rodents, control animals plus J147 were not included in these
experiments. Mice were assayed for memory deficits in the MWM
and for pathological and biochemical changes after 5 additional
months on J147 or control diet. In the acquisition task portion of
the MWM, an assay for learning [34], the transgenic mice showed
deficits that were corrected by treatment with J147 (Fig. 5A). Since
these were older animals, even the non-transgenic littermate
control mice were relatively slow learners [35]; [36]. However, by
day 5 the mice with J147 diet had learned the task, while the
untreated AD mice did not. In the probe trial, an assay for spatial
memory, there was also significant improvement, with the J147
diet restoring memory of the platform location to control levels
(Fig. 5B).
J147 Reduces Soluble Ab Levels in the Hippocampus
Since some compounds that reduce memory loss in AD mice
reduce Ab plaque burden, we next examined plaque size and
density as well as Ab levels in the RIPA insoluble (100,0006g
pellet) and soluble (RIPA supernatant) fractions of the hippocampi
of J147 treated and control huAPP/PS1 mice. Neither Ab1–42 nor
Ab1–40 levels as measured by ELISA, were altered in the RIPA
insoluble fraction in animals fed J147 relative to untreated AD
transgenic animals (Fig. 5D). Although there was no difference in
plaque size between control and J147 treated animals, the average
area occupied by plaques and the total number of plaques in each
group was significantly different (Fig. 6). Therefore, while
treatment with J147 enhanced the cognitive ability of the
huAPP/PS1 mice, it had no significant effect on insoluble Ab
levels but a small but significant reduction of plaque load.
However, it is now thought that soluble Ab polymers are major
contributors to the toxicity associated with the peptide [37].
Figure 5E and F show that the J147 diet reduces the amount of
RIPA soluble Ab1–40 and Ab1–42 in the hippocampus and
Figure 5C demonstrates a reduction in Ab polymers, detected
by the 6E10 antibody, in the 40–60,000 molecular weight range in
the transgenic mice fed J147 relative to control animals on a drug-
free diet. It follows that J147 has a small but significant effect on
Ab metabolism by reducing Ab1–42 in the soluble fraction of the
hippocampus.
Figure 5. J147 Improves Learning and Short-Term Spatial Memory. Line 85 mice were fed J147 at 200 ppm between 3 and 10 months of age
and then assayed for learning and memory in the Morris water maze. (A) Task acquisition phase. Data are expressed as standard deviation 6 SEM and
analyzed by ANOVA of repeated measures. F(2,14)=8.3. **P,0.01 AD vs AD+J147; P,0.05 AD vs. control. (B) Probe test. One-way ANOVA
F(2,54)=16.6. **P,0.001 AD vs AD+J147; P,0.05 AD vs. control. These data show that both wild type and line 85 mice are slow learners, but that
J147 corrects the deficit in both learning (day 5) and their spatial memory (probe test). (C) Ab oligomers between 30 and 50 kD in soluble fraction
from AD (left 2 lanes) and AD+J147 (right 2 lanes) animals. J147 treatment decreased these oligomers. Two-tailed P value, *P,0.05. Ab1–40 and Ab1–42
levels were measured by ELISA in control AD animals (open bars) and AD animals fed J147 (hatched bars) in the insoluble (100,0006g pellet) (D) and
RIPA soluble fractions (E and F). J147 treatment decreased both soluble Ab1–40 and Ab1–42 levels. Two-tailed P values *P,0.05; **P,0.01; *** P,0.001.
All data shown are means 6 SEM. n=6 to 9 mice per group.
doi:10.1371/journal.pone.0027865.g005
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As outlined in the Introduction, the biochemical profile of the
brain changes with age and many pathological aspects of the aged
brain are enhanced in AD. Specifically, there is an increase in pro-
oxidants and markers of oxidative stress as well as inflammation,
and these have been associated with a decline in cognitive skills,
both in AD and normal aging [38] [39]. At the same time, cells in
the AD brain are trying to survive the pathological insults
associated with the disease by increasing their neuroprotective
mechanisms. It is the relative balance of the two processes that
determines the fate of the individual cell. A successful AD drug
should alter this balance in favor of survival, returning expression
levels of the molecules involved to control values. To determine if
J147 is able to alter any markers for oxidative stress in huAPP/PS1
transgenic mice, Western blots of hippocampal tissue were carried
out to determine the expression levels of several stress-related
proteins. Figure 7A shows that there is a large increase in heme
oxygenase 1 (HO-1) in huAPP/PS1 mice that was decreased to
control levels by J147. HO-1 is frequently thought of as an
antioxidant enzyme [40], but it is elevated in AD brain and can act
as a pro-oxidant under some conditions [41]. Microglia mediate a
significant part of the inflammatory immune response in the CNS
and are activated and increased in number in AD [39].
Biochemical markers for microglia include Iba-1 and inducible
nitric oxide synthase (iNOS). Figure 7B shows that there is a
significant reduction in the amount of Iba-1 in the hippocampus of
J147-treated huAPP/PS1 mice relative to control huAPP/PS1
mice while the reduction of iNOS is not quite statistically
significant due to the large mouse to mouse variability with this
marker (Fig. 7C). Finally, 5-lipoxygenase (5-LOX) is responsible
for the synthesis of leukotrienes that are potent mediators of
inflammation and chemotaxis of immune cells [42], and are
overexpressed in AD [43]. 5-LOX is highly upregulated in the
huAPP/PS1 mice and brought down to control levels by J147
(Fig. 7D). Together these data suggest that J147 is able to
modulate the level of oxidative stress and the inflammatory
response in huAPP/PS1 mice.
J147 Reduces Heat-Shock Proteins and Increases
Synaptic Protein Expression
Oxidative stress damages proteins and degrades their ability to
fold properly. To compensate, cells increase the synthesis of
proteins that promote proper folding, including members of the
Figure 6. Immunohistochemical analysis of condensed Ab deposits. Immunohistochemical analysis was done using brain coronal sections of
13-month old AD mice on control diet (A) or J147 diet (B) using antibody 6E10. In comparison to AD control mice (A), condensed Ab deposits were
significantly reduced in the hippocampus region of AD mice on J147 diet (B). 30 micron thick sections of similar regions from each mouse, (n=6)
were examined and plaque counts in the hippocampus were quantified. All images were quantified using Image J Software. (C) The average of
plaque counts for each mouse group is expressed as a number of plaques 6 the SD (n=6 per group: unpaired t-test, *P,0.05). (D) Reduced Ab
plaque load in AD mice on J147 diet. The Ab plaque load was determined by measuring the area occupied by Ab-immunoreactive condensed
deposits, (n=6 per group: unpaired t-test, *P,0.05). (E) The plaque size did not change between AD mice on control and J147 diets (n=6 per group:
unpaired t-test, *P.0.05).
doi:10.1371/journal.pone.0027865.g006
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expression of the heat shock family of chaperones and the co-
chaperone HOP [44]. Figure 8A–C shows that the levels of
HSP70, 90 and the co-chaperone HOP are increased in huAPP/
PS1 mice and decreased to control levels by J147.
To obtain some insight into the structural basis of the protection
from cognitive loss afforded by J147, the expression of three major
synaptic proteins was examined. Drebrin, synapsin 1 and
synaptophysin were chosen because their loss has been correlated
with both human AD and behavioral deficits in transgenic mouse
lines [45]; [46]; [47]. Figure 8D–F shows that all three proteins are
reduced in huAPP/PS1 mice and their levels brought to control
levels or higher by J147.
BDNF is Up-Regulated by J147
J147 was synthesized and selected for its ability to act as a
neurotrophic factor in part using assays where it can replace the
function of BDNF. It was therefore asked if J147 is able to increase
Figure 7. J147 Reduces Pro-oxidant Enzymes in the Brains of huAPP/PS1 mice. Cell lysates of hippocampal tissue from huAPP/PS1 and
control mice were analyzed by western blotting and the images quantified. C=control; A=AD transgenic; A+=AD transgenic fed J147. (A) Heme
oxygenase-1 is increased in AD transgenic mice compared to control and these levels are decreased in mice fed J147. (B) Iba-1 levels are decreased in
AD transgenic mice fed J147. (C) iNOS levels are not quite significantly decreased in AD transgenic mice fed J147. P=0.053. (D) 5-LOX is significantly
decreased in AD transgenic mice fed J147. *P,0.05, **P,0.01, and ***P,0.001. All data shown are means 6 SEM, n=5 per group.
doi:10.1371/journal.pone.0027865.g007
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downstream signaling pathways. J147 increases the levels of BDNF
in the hippocampus of both normal rats (Fig. 9A) as well as in
huAPP/PS1 transgenic mice (Fig. 9B). BDNF directly regulates
the expression of several genes involved in synaptic spine
formation as well as the phosphorylation of proteins involved in
learning and memory [48]. Homer 1 is an actin binding protein
that is induced by BDNF [49]. Figure 9C shows that J147 restores
the expression of this protein relative to untreated huAPP/PS1
mice. The phosphorylation of the scaffold protein PSD95 is
mediated by BDNF [50]. Figure 9D shows that J147 greatly
increases the phosphorylation of PSD95 at Tyr 236 and 240 in
huAPP/PS1 mice relative to both control and untreated AD mice.
J147 does not, however, require the expression of the BDNF
receptor TrkB for its neuroprotective activity (Fig. 2B) and the
levels of TrkB in the AD mice are not altered by J147 (not shown).
Figure 8. J147 Reduces Heat Shock Protein Stress Response and Increases Markers for Synaptic Function. Cell lysates from
hippocampal tissue of line 85 mice fed J147 for 7 months were analyzed by Western blotting. C=control; A=AD transgenic; A+=AD transgenic fed
J147. (A) HSP90 levels are decreased in AD transgenic mice fed J147. (B) HOP levels are decreased in AD transgenic mice fed J147. (C) HSP70 levels are
increased in AD transgenic mice and these levels are decreased with treatment of J147. (D) Drebrin levels are decreased in AD transgenic mice and
J147 treatment restores levels to above control levels. (E) Synapsin-1 levels are decreased in AD transgenic mice and are restored significantly beyond
control by J147. (F) Synaptophysin levels are decreased in AD transgenic mice and levels are restored beyond control levels with J147. *P,0.05,
**P,0.01), and ***P,0.001. All data shown are means 6 SEM, n=5 per group.
doi:10.1371/journal.pone.0027865.g008
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and modulates the expression and/or phosphorylation of down-
stream targets of BDNF.
Discussion
Familial AD (FAD) is caused by mutations in a small subset of
genes that control the generation of Ab [51]. Because of these
findings, it is widely believed that Ab is the causative factor in AD
and the vast majority of the drug development effort for AD is
focused upon Ab or components of the Ab biosynthetic pathway.
While Ab is clearly relevant, over 95% of all AD cases are not
FAD and age is by far the greatest risk factor for the disease. It is
therefore likely that the various pathological components of old
age such as oxidative stress, the loss of trophic factors, reduced
energy metabolism, and inflammation all lower the threshold for
Ab toxicity. It follows that conditions that reduce these stressors
are likely to delay the onset of AD and/or reduce its consequences
[3]. These age-associated parameters have not, however, been
employed as a group for targeting pathways in AD drug discovery.
To explore the possibility of using these parameters for the
discovery and development of AD drugs, we initially synthesized a
library of hybrid molecules between the multi-target plant
polyphenolic curcumin and a neurotrophic molecule, cyclohexyl-
Figure 9. J147 Increases the Levels of BDNF and BDNF Responsive Protein and Protein Phosphorylation. (A) BDNF expression in the
hippocampus of normal adult rats following two weeks treatment of J147 in food at 200 ppm. J147 treatment increased BDNF levels in the normal
rat. Two-tailed t test. *P,0.05. (B) BDNF expression in hippocampus of huAPP/PS1 transgenic mice fed J147 for 7 months before sacrifice at 10
months. BDNF levels are decreased in AD transgenic mice and treatment with J147 restores levels to beyond control levels. (C) Homer-1 expression in
huAPP/PS1 mice. J147 treatment increases Homer-1 levels. (D) Phosphorylation of PSD95 at Tyr 236, 240. J147 treatment increases phosphorylation of
PSD95 in AD transgenic mice. Data are presented as ratio of phospho PSD95 to total PSD95. *P,0.05, **P,0.01, and ***P,0.001. All data shown are
means 6 SEM. n=5–6 per group. C=control; C+=control + J147; A=AD transgenic; A+=AD transgenic fed J147.
doi:10.1371/journal.pone.0027865.g009
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was neuroprotective in six toxicity assays [8]. Selection was
followed by a limited structure-activity (SAR) analysis of CNB-
001, and a chemical reaction that was able to generate extensive
diversity around the structural components of CNB-001 that the
SAR suggested were required for activity. From the products of
this reaction, we identified one compound, J147, that was active in
the original assays but that had EC50s up to 100 times lower than
CNB-001 in the various selection assays. J147 also has greatly
improved medicinal chemical properties for a CNS drug.
Since two of the six selection assays are directly for neurotrophic
activity, and BDNF is a neurotrophic factor that is reduced in AD
brain and is required for normal memory, we asked if J147 could
modulate hippocampal LTP, memory, and prevent behavioral
deficits in a huAPP/PS1 AD mouse model. Figure 3 shows that
J147 is able to facilitate the induction of LTP in hippocampal
slices. LTP requires a large number of signaling cascades,
including those activated by BDNF [48]. Like J147, exogenous
BDNF promotes, but does not cause LTP [52]. Conversely, LTP is
attenuated in multiple strains of BDNF knockout mice [48]. LTP
is associated with the increased expression of BDNF and of the
BDNF responsive gene, Homer 1. BDNF also increases the
phosphorylation of PSD95. J147 mimics BDNF by both
maintaining Homer 1 expression and increasing the phosphory-
lation of PSD95 in AD transgenic mice (Fig. 9 C and D). Because
J147 has both long- and short-term biological effects, as well as in
multiple cell culture aging/disease models, it is likely that efficacy
is the result of pleiotrophic mechanisms. For example, BDNF-like
neuroprotective activity does not require the expression of the
BDNF receptor (Fig. 2B), but it is able to induce BDNF expression
in vivo. In addition, the in vivo metabolites of J147 have the same
biological activities as the parent, which may contribute to its long-
term efficacy (in preparation).
The normal aging process is often associated with a reduction in
learning and memory, so it would be very useful for an AD drug to
also enhance non-pathological memory loss. Several different
types of memory tests that assess aspects of memory in humans can
be performed in rodents [53]; [54]; [55]. Working memory is
assessed using the Y-maze [56], spatial memory using the Morris
water and Barnes mazes [57], and recognition memory by using
the novel object recognition test [58]. J147 has broad cognitive
enhancing effects, including enhanced working memory, object
recognition and spatial memory in healthy adult rodents (Fig. 4).
J147 also prevented the spatial learning and memory deficits
observed in AD transgenic mice (Fig. 5A and B). While there are
many cognitive enhancing drugs that regulate aspects of synaptic
transmission [59], J147 is a novel candidate, for it is neither a
phosphodiesterase nor an acetylcholinesterase inhibitor.
There is an extensive literature showing that the BDNF
signaling pathway is a major component of learning and memory
[60]. BDNF is highly expressed in the hippocampus [61], and
cognitive enhancement paradigms such as exercise enhance pro-
BDNF, BDNF, and BDNF mRNA in the hippocampus [62], [63].
Recently, it has been argued that individuals who get regular
exercise are less prone to AD [64]. Conditional BDNF gene
deletion in adult mice causes impaired learning and memory in
multiple assays, confirming its role in cognition [65], [66]. In
addition, BDNF may enhance synaptic efficacy by promoting
synaptic spine growth and stability, including the growth of new
spines that increase synaptic density along neurites [67]. J147
maintains the expression of synaptophysin, a synaptic vesicle
protein that is reduced in both aging and AD, and is considered an
excellent marker for synapse loss (Fig. 8F) [68], [45]. J147 also
prevents the loss of drebrin and synapsin-1 in the huAPP/PS1
animals (Fig. 8D and E). Drebrin is an actin binding protein that is
enriched in synaptic spines that also declines with age and AD [69]
and synapsin-1 is a membrane protein that is involved in synaptic
vessel release [70]. These data show that J147 not only has the
ability to enhance memory in both normal and AD mice, but to
increase the expression of the protein substrates for memory.
Both oxidative stress and inflammatory markers are enhanced
in human AD brain [71] as well as in AD transgenic mice [72].
The interpretation of biochemical markers for oxidative stress in
the AD brain is, however, somewhat complicated because there
are two populations of cells at the extremes of viability, one
expressing the genes associated with a survival response and
another reflecting activated cell death pathways. In the case of
inflammation, a modest activity may be neuroprotective, for
example amyloid phagocytosis by activated microglia or macro-
phages, while a more robust inflammatory response will be
destructive. Therefore, from a therapeutic point of view, it is best
to return the expression of the proteins involved to the pre-AD
control level.
We examined four indicators of oxidative stress and inflamma-
tion in control, huAPP/PS1 and J147-treated huAPP/PS1 mice.
Heme oxygenase 1 (HO-1) is elevated in AD [73], and in the AD
transgenic animals (Fig. 7A); J147 reduces expression to below
control levels. Iba-1, a marker for microglia is significantly
elevated in AD mice and reduced by J147, while a toxic microglial
enzyme, iNOS, is not quite significantly reduced by J147 (Fig. 7B,
C). Finally, 5 LOX is a potent reactive oxygen species (ROS)
producing and pro-inflammatory enzyme that is increased in AD
[74], [75]. This enzyme is also increased in the transgenic mice but
levels are dramatically reduced by J147 (Fig. 7D). Together these
data show that J147 is able to normalize several aspects of the pro-
inflammatory and pro-oxidant conditions in the transgenic
animals.
Finally, AD can be viewed as a protein misfolding disease that
leads to the aggregation of many proteins, including Ab, resulting
in toxicity and, ultimately, cell death. Under conditions of stress,
heat shock proteins 70 and 90 are induced to enhance protein
clearance. HOP-1 (also called stress-inducible protein 1) is a co-
chaperone that interacts with HSP70 and HSP90 families. HOP-1
plays crucial roles in the productive folding of substrate proteins by
controlling the chaperone activities of HSP70 and HSP90.
Figure 8A, B, and C show that all three proteins are elevated in
huAPP/PS1 mice and that J147 reduces their expression. The
ability of J147 to lower the expression of heat shock proteins in AD
transgenic mice again suggests that this unique compound has the
ability to normalize multiple aspects of AD pathology.
Conclusions
The above data demonstrate the potential of a new drug
discovery paradigm for AD that is based upon the requirement
that drug candidates be highly effective in multiple, distinct cell
culture models of neurodegeneration. This approach yielded a
very potent, orally active drug candidate that targets several
different pathways that decline in AD. A large number of potential
pharmaceutical, nutritional, and immunological therapies have
been tested in clinical trials for AD, but to date they have not
altered cognitive decline in humans [76]. In contrast, over 200
compounds appear to reduce plaque loads or behavioral deficits in
AD transgenic mice [77] and several compounds increase the
amount of BDNF in rodent brain [78]. However, none of these
compounds nor any of the drugs that are in clinical trials for AD
have the combination of activities of J147 in cell culture and in
animals ([78]; [79]; http://clinicaltrials.gov). J147 is unique in its
ability to enhance LTP, potentiate learning and memory in both
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proteins while at the same time reducing biochemical markers of
inflammation and soluble Ab levels in AD transgenic mice.
Therefore, the range of biological activities of J147 relevant to
human AD is also much more extensive than any of the
compounds that have failed in clinical trials. In addition, J147 is
very potent, has good medicinal chemical properties for a CNS
drug [14], is apparently safe, and is orally active. Finally, unlike the
current drugs approved for AD, J147 is neither an acetylcholine
esterase inhibitor, an NMDA receptor antagonist, nor a
phosphodiesterase inhibitor, yet it enhances cognition with a
short-term treatment. Thus J147 is an exciting new compound
with the potential to be an AD therapeutic by slowing disease
progression through neuroprotection as well as providing
immediate cognition benefits. These dual attributes improve the
chances for success as a disease-modifying drug as well as in short-
term AD clinical trials that use currently accepted approvable
measures of outcome.
Materials and Methods
Materials
High glucose Dulbecco’s modified Eagle’s medium (DMEM)
and fetal calf serum were from Invitrogen (Carlsbad, CA, USA).
All other reagents were purchased from Sigma (St Louis, MO,
USA). The transmembrane receptor kinase B (TrkB)-expressing
HT22 cells were obtained from Dr Gerard Thiel (Homburg,
Germany). The transgenic mouse line 85 was a generous gift of
Dr. J.L. Jankowsky.
The primary antibodies were used at a dilution of 1:1000 unless
otherwise stated and their sources and molecular weights were as
follows: Cell Signaling Technology (Danvers, MA): HOP (poly-
clonal, 60 kDa), Synaptophysin (polyclonal, 40 kDa) and phospho
PSD95 (polyclonal, 95 kDa). Santa Cruz Biotechnology (Santa
Cruz, CA): Thio Reductase-1, 1:10000 (polyclonal, 55 kDa) and
BDNF (polyclonal, 16 kDa). BD Biosciences (Rockville, MD):
iNOS (monoclonal, 135 kDa) and synapsin-, 1, 1:10000 (mono-
clonal, 80 kDa). Cayman Chemicals (Ann Arbor, Michigan): 5-
LOX (polyclonal, 78 kDa) and 12/15 LOX (polyclonal, 75 kDa).
StressMarq Biosciences Inc. (Victoria, BC, Canada): HS90
(monoclonal, 90 kDa) and HS70 (monoclonal, 70 kDa). Wako
(Richmond, VA): Iba-1 (polyclonal, 16 kDa). Abcam (Cambridge,
MA): Drebrin (monoclonal, 2 major bands at 50 and 100 kDa).
Novus Biologicals (Littleton, CO): Homer-1 (polyclonal, 40 kDa).
Sigma (St Louis, MO): anti-actin 1:40000 (polyclonal,45 kDa).
Stressgen (now Enzo Life Sciences) (Plymouth Meeting, PA):
Heme oxygenase-1(HO-1) (polyclonal, 28 kDa).
Methods
Ethics Statement. Experiments involving rodents were
conducted following protocols approved by the Salk Institutional
Animal Care and Use Committee (Protocol Number 09-025).
Cell Culture Assays
Trophic Factor Withdrawal. Primary cortical neurons were
prepared from 18-day-old rat embryos according to published
procedures [80] and cultured at a low cell density of 1610
6/
35 mm dish in DMEM/F12 (2 mL) containing N2 supplements
(Invitrogen) and the compounds to be assayed. Viability was
assayed 2 days later using a fluorescent live-dead assay (Molecular
Probes, Eugene, OR, USA) and the data is presented as the
percentage of input cells surviving.
Serum Starvation Assay. HT22 cells with or without TrkB,
the brain-derived neurotrophic factor (BDNF) receptor [15],
were washed three times in serum-free medium, incubated in
serum-free DMEM with or without the indicated compounds for
2 days and cell viability was determined by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay and compared with that of cells grown in 1% serum,
which inhibited cell division but maintained viability. For the
MTT assay, 10 mLo f2 . 5m g / m LM T Ts o l u t i o nw a sa d d e da n d
incubated at 37uC for 4 hr and then 100 mL of solubilization
solution [50% dimethylformamide and 20% sodium dodecyl
sulfate (SDS), pH 4.8] was added. The next day, the absorption
values at 570 nm were measured.
Oxytosis Assay. HT22 cells were plated at 2610
3 cells per
well in 96-well tissue culture dishes in DMEM plus 10% fetal calf
serum. The following day the test compounds were added in
triplicate at appropriate concentrations. Thirty minutes after
compound addition, 5 mM glutamate was added to initiate the
cell death cascade. Twenty hr later, the MTT assay was
performed. The results are presented as the percentage of the
controls with vehicle alone.
In Vitro Ischemia Assay. HT22 cells were seeded onto 96-
well microtiter plates at a density of 5610
3 cells per well in
DMEM plus 10% FCS. The next day, the medium was
replaced with DMEM supplemented with 7.5% dialyzed FCS
and the cells were treated with 20 mM iodoacetic acid (IAA)
alone. After 2 hr the medium in each well was aspirated and
replaced with fresh medium without IAA but containing the
t e s tc o m p o u n d .2 0h rl a t e r ,v i a b i l i t yw a sm e a s u r e db yt h eM T T
assay.
Glucose Starvation Assay. PC12 cells were washed three
times in serum-free, glucose-free medium and exposed to glucose-
free medium plus or minus the indicated compounds and cell
viability determined 48 hr later using the MTT assay. The data
are presented as viable cell number relative to serum-free, glucose-
containing medium.
Ab Toxicity to Hippocampal Neurons. Primary cultures of
embryonic day 17 rat hippocampal neurons were used to assay a
compound’s ability to directly inhibit Ab toxicity. The hippocampi
were removed, the cells dissociated with trypsin and the cells were
plated at 2610
6 per 35 mm polyornithine-coated tissue culture
dish in 10% fetal calf serum, and 2 days later 10 mg/mL Ara C
was added to inhibit glial proliferation. At day 7, 10 mM pre-
aggregated Ab1–42 was added with or without the test compound
and viability determined 2 days later by the lactate dehydrogenase
release assay [80].
LTP Experiments. Slice preparation and field potential
recording were made as described [81]. Briefly, hippocampal
slices (400 mm) were prepared from male Wistar rats (5–7 weeks
old) and maintained in a chamber at 30uC, where they were
continuously perfused with artificial cerebrospinal fluid consisting
of (in mM); 124 NaCl, 4 KCl, 2.4 CaCl2, 1.3 MgSO4, 1.24
NaH2PO4, 26 NaHCO3, and 10 glucose, bubbled with 95% O2/
5% CO2. The Schaffer collaterals were stimulated by a bipolar
tungsten electrode positioned in the stratum radiatum of the CA1
region near the CA2/CA1 border, and the field excitatory
postsynaptic potentials (fEPSPs) were recorded from the stratum
radiatum of the CA1 region. The stimulus intensity was adjusted
in the range of 25–55 mA to evoke fEPSPs of 50% of the
maximum amplitude. Tetanic stimulation was applied at the same
intensity with the test stimulation. The rising slope of fEPSP was
measured as an index of synaptic efficacy. To compare the data
among the groups, the averages of the fEPSP slopes 30–60 min
after tetanic stimulation were calculated as an index of LTP
magnitude. Data were analyzed by one-way ANOVA followed by
the Dunnett’s test.
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Enzyme assays for PDIs and acetylcholine esterase were done
by MDS Pharma Services (Taiwan) and Caliper Life Sciences
(Hanover, MD), respectively.
Behavioral Assays
All animal studies were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of the Salk Institute for Biological Studies and The
Scripps Research Institute.
Rat Novel Object Recognition Test. Male Sprague-Dawley
rats (175–200 grams) (Jackson Laboratory, Bar Harbor, ME) were
used, and the testing was done by Behavioral Pharma, Inc. (La
Jolla, CA). All rats were acclimated to the colony room for at least
2 weeks before testing, and they were tested at an average age of 8
weeks. Rats were randomly assigned across treatment groups with
12 in each group. For each dose tested, a solution of J147 was
prepared in 95% ethanol, and then it was diluted with 4 volumes
of polyethylene glycol 660 hydroxystearate (Solut HS15 from
BASF, Florham Park, NJ) and 5 volumes of PBS. The vehicle
contained the identical ratios of ethanol, Solut HS15, and PBS. All
were administered orally 60 min before the training trial at a
volume of 10 ml/kg of body weight. Galantamine was dissolved in
10% DMSO, and it was administered i.p. at 3 mg/kg 20 min
before training. The test was performed as described by
Bourtchouladze et al. [82]. Briefly, on day 1, rats were
habituated to a circular open field arena for 1 hr in cage groups
of four. Twenty-four hr later, individual rats were placed back in
the same arena, which now contained two identical objects for a
15-min training trial. On day 3, vehicle-, J147, or galantamine-
treated rats were individually placed back in the same arena in the
presence of both the familiar object (i.e., previously explored) and
a novel object. The spatial positions of the objects were counter
balanced between subjects. Each animal’s test trial was recorded,
and the first 10 min of each session were scored. Object
recognition was computed by using the following formula: Time
spent exploring the novel object divided by total time spent
exploring both objects 6100. Data were analyzed by a one-way
ANOVA followed by post hoc comparisons with Fisher’s test.
Mouse Behavioral Testing. For the Barnes maze, Y maze
and NOR tests, male C57BL/6J mice were provided J147 in
standard rodent chow (N=12) or were given control feed (N=12)
starting at 6 weeks of age. Body weights were determined before
and during the experimental sequence. Barnes maze testing was
initiated 2 weeks into J147 exposure. Y maze and NOL testing
took place 7 and 8 wks into exposure, respectively.
Barnes Maze. The Barnes maze apparatus is an opaque
Plexiglas disc 75 cm in diameter elevated 58 cm above the floor by
a tripod. Twenty holes, 5 cm in diameter, are located 5 cm from
the perimeter, and a black Plexiglas escape box (196867 cm) is
placed under one of the holes. Distinct spatial cues are located all
around the maze and are kept constant throughout the study.
On the first day of testing, a training session was performed,
which consists of placing the mouse in the escape box for one
minute. After the one minute habituation period, the first session
was started. At the beginning of each session, the mouse was
placed in the middle of the maze in a 10 cm. high cylindrical black
start chamber. After 10 seconds the start chamber was removed, a
buzzer (80 dB) and a light (400 lux) were turned on, and the
mouse was set free to explore the maze. The session ended when
the mouse entered the escape tunnel or after 3 min elapsed. When
the mouse entered the escape tunnel, the buzzer was turned off
and the mouse was allowed to remain in the dark for one minute.
When the mouse did not enter the tunnel by itself it was gently put
in the escape box for one minute. The tunnel was always located
beneath the same hole (stable within the spatial environment),
which was randomly determined for each mouse. Mice were tested
once a day for 9 days for the acquisition portion of the study.
Six weeks later the mice were tested again with the escape box
in the original position (retention test). This allowed for the
examination of long-term memory. Finally, on the day after this
test, the escape tunnel was moved to a new location (90 degrees
from the original position) and the behavior of the mouse was
recorded. This is called the reversal test and it allowed for the
examination of the strategies adopted by the mouse to locate the
new tunnel location.
Each session was videotaped and scored by an experimenter
blind to the treatment group of the mouse. Measures recorded
included latencies to escape, the number of errors made per
session and the strategy employed by the mouse to locate the
escape tunnel. Errors are defined as nose pokes and head
deflections over any hole that did not have the tunnel beneath
it. Search strategies are determined by examining each mouse’s
daily session and classifying it into one of three categories: 1)
Random search strategy – localized hole searches separated by
crossings through the center of the maze, 2) Serial search strategy
– systematic hole searches (every hole or every other hole) in a
clockwise or counterclockwise direction, or 3) Spatial search
strategy - reaching the escape tunnel with both error and distance
(number of holes between the first hole visited and the escape
tunnel) scores of less than or equal to 3. Barnes maze data were
analyzed by repeated measures analysis of variance and group
differences in individual time blocks and the retention and reversal
trials were compared using Student’s t-tests. Two proportion z-
tests were used to compare strategies employed between groups.
Novel Object Location Test. Mice were tested in an open
field apparatus (79679650.8 cm) with a small bottle placed in one
location for four 5 min trials. For the 5
th trial, the object was
moved to a different spatial location. The inter-trial interval was
1 min. All behavior was video recorded and then scored for
number of object contacts (touching with nose or nose pointing at
object and within 0.5 cm of object). The data are presented as
recognition index (see above) and analyzed using the Student’s t-
test.
Y-Maze Test. For the Y maze test for spontaneous
alternations the same mouse groups were used as with the
Barnes maze on NOL tests. Spontaneous alternation, the tendency
to alternate free choices in a Y-maze (3 arms), is a model for
studying working memory in mice. A single 5 min test was
performed in which each mouse was placed in the center of the Y.
Arm entries were recorded by video camera and the total number
of arm entries and the order of entries were determined.
Spontaneous alternations are defined as consecutive triplets of
different arm choices. Y maze data were analyzed using Student’s
t-tests.
huAPPswe/PS1DE9 Transgenic Mice
Animals. The APP/PS1 transgenic mice (line 85) have been
previously characterized [83]. The line 85 mice carry two
transgenes, the mouse/human chimeric APP/Swe, linked to
Swedish FAD and human PS1DE9. At three months of age
male transgenic mice and their wild type littermates were fed high
fat diet (Harlan Teklad, Madison, WI) with and without J147
(200 ppm). Mouse body weights and food consumption were
measured weekly, and there were no significant differences
between the groups.
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month old huAPPswe/PS1 transgenic mice fed J147 at 200 ppm
in food for the previous 5 months using the Morris water maze
(MWM). The MWM procedure was 4 trials per day for 5
consecutive days. For each trial, mice were placed in the pool at 1
of 4 start locations. The starting locations were separated by 90u
and will be identified as south, west, north, and east. Mice started a
trial once from each of the 4 possible start locations on each day.
The goal platform was positioned 45 cm from the outside wall in
the south quadrant of the maze for all groups. The latency to find
and mount the hidden platform was used as the primary
dependent variable. Swimming speeds were recorded to assess
drug-induced motor effects. Mice were given a maximum of 120 s
to find the hidden platform. If the mice failed to find the platform
after 120 s, they were placed on the platform by the experimenter.
All mice remained on the platform for 15 s before being placed in
a heated incubator (30uC) between trials. Personnel evaluating
animals in the MWM were blinded to the injury and drug
treatments of each animal. A mean daily latency to find the goal
platform during MWM testing was computed for each mouse. On
day 6, a probe test was done in which the platform was removed
and the time spent in the platform quadrant determined. Analysis
of latency times was done by ANOVA of repeated measures. Days
are within the subjects factor and group is between the subjects
factor. A significance level of P,0.05 was considered significant.
Tissue Preparation and Immunoblotting. Hippocampal
tissue samples were homogenized in 10 volumes of RIPA lysis
buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% sodium
dodecyl sulfate and 0.5% deoxycholate, and 1% NP40)
containing a cocktail of protease and phosphatase inhibitors
[20 mg/ml each of pepstatin A, aprotinin, phosphoramidon, and
leupeptin; 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride
hydrochloride; 1 mM EGTA; 5 mM fenvalerate; and 5 mM
cantharidin]. Samples were sonicated (2610 s) and centrifuged at
100,0006g for 60 min at 4uC.
Protein concentrations in the cell extracts were determined
using the BCA protein assay (Pierce). Equal amounts of protein
were solubilized in 2.56SDS-sample buffer, separated on 12% or
10–20% SDS-polyacrylamide gels, transferred to Immodulin P
and immunoblotted with the antibodies indicated in Materials. For
western blots, protein levels were normalized to actin levels.
ANOVA analysis with the Tukey post hoc test was used to
determine differences between means for Western blot analysis.
Immunohistochemistry. Brains were fixed with 4%
paraformaldehyde in 100 mM sodium tetraborate, pH 9.5, for
3 h, cryoprotected with 20% sucrose-potassium-PBS (KPBS), and
cryostat sectioned into coronal (30 mm) sections. Sections were
submerged in 0.3% H2O2 for 10 min to eliminate endogenous
peroxidase activity and treated with 1% borate to eliminate free
paraformaldehyde. Sections were incubated with primary
antibody in 0.3% Triton X-100 in KPBS plus 2% filtered serum
or BSA overnight at 4uC, and with primary antibodies (1:1000) in
0.3% Triton X-100 for 1 hr at room temperature. After
incubation with secondary antibody and ABC reagent (Vector
Laboratories), sections were developed using metal-enhanced
DAB solution. Sections were mounted to slides, dried,
dehydrolyzed, treated with xylene, and covered using dibutyl
phthalate xylene. Images were captured by a Zeiss digital camera
connected to a Zeiss VivaTome microscope, and image analysis
on sections was performed using Axiovision software.
Quantification of amyloid plaque burden was based on the
image captured by immunohistochemical staining with antibody
6E10. Sections of each mouse cortex and hippocampus were
imaged together and the areas and densities of the plaques in the
hippocampus only were measured by the Image J software (NIH).
The total counts of Ab plaques in sections per six mouse brains of
each group were determined in an unbiased fashion.
Ab ELISA. Ab 1–40 and 1–42 levels in hippocampal lysate
were analyzed using the Ab1–40 and Ab1–42 ELISA kits from
Invitrogen (# KHB3481 and # KHB3442, respectively). All kit
reagents were allowed to reach room temperature before use.
Standards were prepared according to manufacturers guidelines
and samples were diluted as follows; RIPA fractions were diluted
1:10 for both Ab1–40 and Ab1–42; and RIPA insoluble fractions
were diluted 1:2000 for Ab1–40 and 1:5000 for Ab1–42.5 0mlo fA b
peptide standards and samples were added in duplicate to 96 well
plates pre-coated with mAb to the NH2 terminus region of Ab.
Plates were incubated at 4uC overnight and then 50 mlo fH u
Ab40 or Ab42 detection antibody was added to each well except
the chromogen blanks. Plates were incubated at room temperature
with gentle shaking for 3 hours and then washed 4 times with
provided wash buffer. At this time, 100 ml of Anti-Rabbit IgG
HRP working solution was added to each well except the
chromogen blanks for 30 min at room temperature. Wells were
then washed as before four times and incubated with 100 mlo f
Stabilized chromogen for 25 min at room temperature in the dark.
Stop solution was then added at 100 ml to each well followed by
reading the absorbance of each well at 450 nm. Curve fitting
software was used to generate the standard curve where a four
parameter algorithm provided the best standard curve fit. The
concentrations of the samples were calculated from the standard
curve and multiplied by the dilution factor.
Chemistry
Diversity Synthesis. m-Anisaldehyde (50 mmol, 1 eq.) was
dissolved in dichloromethane (300 ml) under nitrogen and 2,4
dimethylphenyl hydrazine hydrochloride (50 mmol, 1 eq.) was
added and mixed for 30 min. Trifluoroacetic acid (TFA)
(100 mmol, 2 eq.) was added and stirred for an additional hr.
Finally, triacetoxyborohydride (60 mmol, 1.2 eq.) was added along
with 200 ml of additional dichloromethane, and the reaction
stirred overnight under nitrogen. Five hundred ml of water was
added to the orange reaction mixture, and stirred for 1 hr to
dissolve the borohydride salts. The layers were separated in a
funnel, and the organic layer washed three times with 0.1 M
sodium bicarbonate, separated, and dried. The products were
separated into eight spots on silica then layer plates, (hexane-ethyl
acetate solvent), and the most active fraction in the oxytosis, Ab
toxicity and TFW assays run on HPLC (C18 reverse phase 20 to
100% acetonitrile linear gradient in 0.1% TFA) and assayed.
1-(2,4-dimethylphenyl)-2-(3-
methoxybenzylidene)hydrazine hydrochloride (3)
The preparation of J147 is shown in Figure 10. A mixture of
1(115 g, 0.66 mol, 1.0 eq.) and 2(90 g, 0.66 mol, 1.0 eq.) in EtOH
(500 mL) was stirred at RT under N2 for 1 h. A light brown solid
precipitated and was filtered. The solid was washed with EtOH
and methyl butyl ether, dried in vacuo to afford 3 as a light brown
solid (151 g) with a yield of 90%. This unstable compound was
used directly in the next step.
(E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N9-(3-
methoxybenzylidene) acetohydrazide (4)
To a solution of 3(70 g, 0.24 mol, 1.0 eq.), Et3N(85 mL,
0.61 mol, 2.5 eq.) in anhydrous Ch2Cl2(400 mL) trifluoroacetic
anhydride (34 mL, 0.24 mol, 1.0 eq.) was added drop-wise under
N2 while cooled with ice-water. After stirring for 30 min under the
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evaporator, and filtered through a short silica gel column using
petroleum-EtOAc(1:1) as the eluent solvent. The filtrate was
concentrated and re-crystallized from methyl butyl ether to afford
4 as a white solid (65 g) at a yield of 77%.
1H NMR (300 MHz, CDC13): d/ppm=7.32,6.98(m, 8H),
3.84(s, 3H), 2.43(s, 3H), 2.10(s, 3H). MS-ESI: cal. 250; found:
251(M+H
+), 273(M+Na
+), 405(M+Na
++MeOH).
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